{
    "2021-11-22": [
        [
            {
                "time": "",
                "original_text": "天坛生物：静注COVID-19人免疫球蛋白（pH4）目前处于临床试验准备阶段",
                "features": {
                    "keywords": [
                        "天坛生物",
                        "静注COVID-19人免疫球蛋白",
                        "临床试验",
                        "准备阶段"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "天坛生物：“静注COVID-19人免疫球蛋白（pH4）”已获得中国和阿联酋药物临床试验批件",
                "features": {
                    "keywords": [
                        "天坛生物",
                        "静注COVID-19人免疫球蛋白",
                        "临床试验批件",
                        "中国",
                        "阿联酋"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}